Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
复制标题
最大标准化摄取值与原发肿瘤大小的比率是晚期非小细胞肺癌患者的预后因素。
DOI：
10.3978/j.issn.2218-6751.2014.11.02
复制
发表时间：
2015-02-01
影响因子：
4
通讯作者：
Song, Yong
中科院分区：
文献类型：
--
作者：
Chen, Fangfang;Yao, Yanwen;Song, Yong
目的
先前已证明，在手术切除的非小细胞肺癌 (NSCLC) 中，最大标准化摄取值与原发肿瘤大小的比率（SUVmax/肿瘤大小）比单独的原发肿瘤 SUVmax 更重要。本研究的目的是调查 SUVmax/肿瘤大小是否与晚期 NSCLC 患者对一线治疗的反应和预后相关。
患者和方法
对在接受一线治疗的晚期 (III 和 IV) NSCLC 患者之前接受过 (18)F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描 ((18)F-FDG PET/CT) 预处理的患者进行了回顾性评价。通过 Kaplan-Meier 方法按中位 SUVmax 和 SUVmax/肿瘤大小对生存曲线进行分层，并使用对数秩检验评估统计差异。应用多变量比例风险 (Cox) 回归分析来测试 SUVmax 和 SUVmax/肿瘤大小与预测生存的其他预后因素的独立性。
结果
共有 181 名患者参加了当前的研究。中位总生存期（OS）为15.4个月（范围，3.1-64.0个月），无进展生存期（PFS）为5.6个月（范围，0.8-29.1个月），进展后生存期（PPS）为8.2个月（范围，0-51.3个月）。统计分析数据表明，只有一线治疗的临床反应（P=0.000，OR=6.555）是PFS的独立预后因素，分期（P=0.028，OR=1.673）与PPS独立相关，而对于OS，SUVmax/肿瘤大小（P=0.050，OR=1.656）和临床反应（P=0.002，OR=2.803）都是独立的预后因素。独立预后 因素。
结论
SUVmax/肿瘤大小可能是晚期NSCLC患者预后的重要指标。
PURPOSE
Ratio of maximum standardized uptake value to primary tumor size (SUVmax/tumor size) was previously demonstrated to be a more important indicator of prognosis than primary tumor SUVmax alone in surgically resected non-small cell lung cancer (NSCLC). The aim of this study was to investigate whether SUVmax/tumor size was associated with response to first-line therapy and prognosis in patients with advanced NSCLC.
PATIENTS AND METHODS
A retrospective review of patients who had a pretreatment (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) before receiving first-line therapy for advanced (III & IV) NSCLC was performed. Survival curves were stratified by median SUVmax and SUVmax/tumor size by the Kaplan-Meier method and statistical differences were assessed using the log-rank test. Multivariate proportional hazards (Cox) regression analyses were applied to test the SUVmax's and SUVmax/tumor size's independency of other prognostic factors for the prediction of survival.
RESULTS
In total 181 patients were enrolled into the current study. Median overall survival (OS) was 15.4 months (range, 3.1-64.0 months), progression-free survival (PFS) was 5.6 months (range, 0.8-29.1 months), and post-progression survival (PPS) was 8.2 months (range, 0-51.3 months). The statistical analysis data indicated that only clinical response to first-line therapy (P=0.000, OR =6.555) was independent prognostic factors for PFS, stage (P=0.028, OR =1.673) was associated with PPS independently, and for OS, SUVmax/tumor size (P=0.050, OR =1.656) and clinical response (P=0.002, OR =2.803) were all independent prognostic factors.
CONCLUSIONS
SUVmax/tumor size may be an important indicator of prognosis in patients with advanced NSCLC.